Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

Edith A. Perez, MD
Published: Thursday, Dec 08, 2011

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, expresses that in order to increase the outcomes for breast cancer patients there has been a push toward targeted approaches, such as those used in the CLEOPATRA trial.

The CLEOPATRA trial, a phase III double-blind study of 808 women, included patients that were eligible to receive a first-line treatment for HER2-positive metastatic breast cancer. The trial randomly added placebo or pertuzumab, an inhibitor of HER2 dimerization, to docetaxel and trastuzumab (Herceptin).

The addition of pertuzumab helped delay tumor progression. The pertuzumab arm experienced a median progression-free survival (PFS) of 18.5 months, compared to 12.4 months in the placebo group. Perez adds the increase in PFS did not entail any additional adverse events and potentially resulted in an overall survival (OS) benefit. She remarks the OS benefit will require further study in order to determine if this is indeed the case.


>>>Return to the main conference coverage page.
Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, expresses that in order to increase the outcomes for breast cancer patients there has been a push toward targeted approaches, such as those used in the CLEOPATRA trial.

The CLEOPATRA trial, a phase III double-blind study of 808 women, included patients that were eligible to receive a first-line treatment for HER2-positive metastatic breast cancer. The trial randomly added placebo or pertuzumab, an inhibitor of HER2 dimerization, to docetaxel and trastuzumab (Herceptin).

The addition of pertuzumab helped delay tumor progression. The pertuzumab arm experienced a median progression-free survival (PFS) of 18.5 months, compared to 12.4 months in the placebo group. Perez adds the increase in PFS did not entail any additional adverse events and potentially resulted in an overall survival (OS) benefit. She remarks the OS benefit will require further study in order to determine if this is indeed the case.


>>>Return to the main conference coverage page.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x